Scientists Engineer Bacteria as 'Trojan Horses' to Smuggle Cancer-Killing Viruses Past Immune Defenses

Scientists have engineered bacteria to act as microscopic Trojan horses, smuggling cancer-killing viruses past the immune system and directly into solid tumors. By combining the tumor-seeking instincts of bacteria with the destructive power of oncolytic viruses, researchers have developed a delivery platform that bypasses one of the most stubborn hurdles in modern oncology. For decades, the fundamental challenge of using viruses to fight cancer has not been the viruses' ability to kill malignant cells, but rather the delivery mechanism. The human body is exceptionally good at clearing viral invaders, meaning therapeutic payloads are often neutralized in the bloodstream before they ever reach their target. This new dual-microbe approach effectively cloaks the virus inside a living bacterial courier, allowing it to navigate the bloodstream undetected, infiltrate the tumor's core, and unleash a targeted attack from the inside out.[1][3]

Oncolytic virotherapy—the use of genetically modified viruses to infect and destroy malignant cells—has long held immense promise as a highly targeted cancer treatment. Unlike traditional chemotherapy, which indiscriminately poisons rapidly dividing cells throughout the body, oncolytic viruses can selectively lyse cancer cells while leaving healthy tissue unharmed. However, the human immune system is highly efficient at detecting and neutralizing foreign viruses before they ever reach the tumor site. When a patient is injected with an oncolytic virus, circulating antibodies and immune cells immediately recognize the threat and clear it from the bloodstream. Because of this rapid clearance, doctors have historically been forced to inject the viruses directly into the tumors, a highly invasive procedure that is impossible for deep-seated or metastasized cancers. Finding a systemic, intravenous delivery method that survives the immune system has been the holy grail of the field.[1][3]

To solve this delivery problem, researchers turned to an unlikely ally: Salmonella typhimurium. While typically associated with foodborne illness, this specific bacterium possesses a unique biological quirk that makes it highly valuable for oncology. Salmonella naturally gravitates toward the low-oxygen, nutrient-rich microenvironments found deep inside solid tumors. Because tumors grow so rapidly, their blood vessels are often poorly formed, creating hypoxic (low-oxygen) zones that are difficult for traditional drugs and immune cells to penetrate. Salmonella, however, thrives in these exact conditions. By hiding the viral payload inside the bacteria, the system effectively creates an "invisibility cloak" that shields the virus from circulating antibodies. The bacteria act as a self-guided transport vehicle, swimming through the bloodstream, evading immune detection, and actively seeking out the darkest, most inaccessible regions of the tumor mass.[1][2]

A team at Columbia Engineering and Rockefeller University recently detailed this groundbreaking approach in the journal Nature Biomedical Engineering. Their system, formally dubbed CAPPSID (Coordinated Activity of Prokaryote and Picornavirus for Safe Intracellular Delivery), utilizes an attenuated, safe strain of Salmonella to transport the RNA genome of Senecavirus A. Senecavirus A is a picornavirus with well-documented cancer-killing properties, particularly against certain aggressive solid tumors. The researchers spent years fine-tuning the genetic modifications required to make the bacteria carry the viral RNA without destroying it prematurely. The resulting platform represents the first synthetically engineered cooperation between prokaryotes and viruses, tailored specifically for safe and targeted tumor destruction. By leveraging the biological strengths of both microbes, the CAPPSID system overcomes the individual limitations that have historically held back both bacterial and viral cancer therapies.[1][2]

The mechanism of action is both elegant and devastating to the tumor. Once the engineered Salmonella bacteria infiltrate the tumor microenvironment, they actively invade the cancer cells. Once safely inside the intracellular space of the malignant cell, the bacteria are programmed to self-destruct in a process called lysis. This suicidal action releases the hidden viral RNA directly into the cancer cell's cytoplasm, completely bypassing the cell's outer defenses. The Senecavirus A RNA then hijacks the cancer cell's own reproductive machinery to replicate itself. As the virus multiplies, it eventually bursts the host cell, killing it instantly. The newly minted viral particles then spill out into the surrounding tumor tissue, infecting neighboring cancer cells and repeating the cycle, creating a cascading wave of destruction that spreads outward from the tumor's core.[1][2]

A critical challenge in any live virotherapy is preventing the virus from spreading uncontrollably throughout the patient's body and causing systemic illness. To address this, the Columbia team engineered a strict, multi-layered biological safeguard into the CAPPSID platform. The Senecavirus A was genetically modified so that it cannot replicate on its own; it strictly requires a specific bacterial enzyme to achieve virion maturation. Because the Salmonella bacteria can only survive within the unique, hypoxic microenvironment of the tumor, the required bacterial enzyme is only present inside the cancer mass. If the virus happens to escape into healthy, oxygen-rich tissue, it finds itself without the necessary bacterial protease and is rendered completely inert. This dependency ensures that the viral infection remains localized entirely within the tumor, providing a crucial safety mechanism for future clinical applications.[1][2]

Parallel research further underscores the viability and versatility of this dual-microbe strategy. A separate team of researchers at the University of Massachusetts Amherst developed a similar platform, utilizing a strain of Salmonella to deliver the H-1 parvovirus. Rather than focusing on lung tumors, the UMass Amherst team specifically targeted liver and pancreatic cancers—two highly aggressive malignancies that are notoriously difficult to treat and carry exceptionally poor prognoses. Their system, known as a virus-delivering Salmonella vector (VDS), demonstrated that the Trojan horse concept is not limited to a single type of virus or a single type of cancer. By swapping out the viral payload and tuning the bacterial carrier, researchers can potentially customize the therapy to attack a wide variety of solid tumors that have previously resisted traditional immunotherapies and chemotherapies.[3]

The data emerging from these early preclinical models is striking in its efficacy. In the UMass Amherst study, animal models treated with the bacteria-virus combination saw profound reductions in tumor burden. The researchers reported that tumors in the treated mice shrank to just 27 percent the size of those treated with Sorafenib, a standard frontline liver cancer drug. Furthermore, the subjects demonstrated significantly extended survival times, living up to 65 days longer than the control groups. In the Columbia University experiments, the CAPPSID system completely eradicated implanted human lung tumors in specific mouse cohorts. Crucially, the UMass team noted that these dramatic effects were achieved using a standard intravenous injection, proving that the bacteria successfully navigated the bloodstream and homed in on the tumors without requiring direct, invasive injections into the tumor mass.[3]

Beyond the direct viral lysis of the cancer cells, the Trojan horse approach triggers a powerful secondary defense mechanism that may prevent cancer recurrence. When the cancer cells burst from the viral infection, they release a flood of tumor-specific antigens and inflammatory signals into the surrounding microenvironment. This chaotic event, known as immunogenic cell death, acts as a massive flare gun for the body's natural immune system. It alerts circulating T-cells and macrophages to the presence of the tumor, effectively training the immune system to recognize and hunt down the specific cancer proteins. This means the therapy not only destroys the primary tumor but also generates a systemic, adaptive immune response. This "vaccine-like" effect could theoretically empower the patient's own immune system to seek out and destroy undetectable micro-metastases scattered throughout the body.[3]

Despite the dramatic preclinical success and the elegance of the biological engineering, the evidence remains strictly confined to animal models and controlled laboratory settings. Human immune systems and naturally forming solid tumor microenvironments are vastly more complex, heterogeneous, and unpredictable than those found in subcutaneous mouse models. It is not yet known how human patients will tolerate the systemic introduction of bacterial vectors, even attenuated ones. There is a significant risk that the bacteria could trigger a severe, systemic inflammatory response or sepsis before they ever reach the tumor. Additionally, while the bacteria shield the virus from antibodies, the human immune system may still mount a rapid attack against the Salmonella itself, potentially clearing the Trojan horse from the bloodstream before it can deliver its payload to the cancer cells.[1]

Furthermore, researchers must verify that the engineered genetic safeguards will remain stable over time. The immense selective pressure of a human body, combined with the rapid mutation rates of both bacteria and viruses, raises the theoretical risk that the microbes could evolve to bypass their built-in safety switches. Extensive safety profiling, dose-escalation studies, and trials in larger mammals will be required to ensure the virus cannot escape the tumor microenvironment and infect healthy tissue. While the current data provides a compelling, paradigm-shifting proof-of-concept that biology still holds untapped tools for oncology, the path to human application is long. Clinical trials in human patients are likely still years away, but the foundation has been laid for a fundamentally new way to deliver targeted cancer therapies.[2]